Grufity logoGrufity logo

BeiGene Ltd Stock Research

BGNE

219.71USD+0.69(+0.32%)Market Closed

Market Summary

USD219.71+0.69
Market Closed
0.32%

BGNE Alerts

BGNE Stock Price

BGNE RSI Chart

BGNE Valuation

Market Cap

298.0B

Price/Earnings (Trailing)

-148.7

Price/Sales (Trailing)

210.43

EV/EBITDA

-159.63

Price/Free Cashflow

-163.53

BGNE Price/Sales (Trailing)

BGNE Profitability

EBT Margin

-138.50%

Return on Equity

-45.71%

Return on Assets

-31.41%

Free Cashflow Yield

-0.61%

BGNE Fundamentals

BGNE Revenue

Revenue (TTM)

1.4B

Revenue Y/Y

77.63%

Revenue Q/Q

-1.94%

BGNE Earnings

Earnings (TTM)

-2.0B

Earnings Y/Y

24.61%

Earnings Q/Q

20.13%

Price Action

52 Week Range

118.18280.62
(Low)(High)

Last 7 days

-2.2%

Last 30 days

-3.2%

Last 90 days

-2.8%

Trailing 12 Months

8.5%

BGNE Financial Health

Current Ratio

3.55

BGNE Investor Care

Shares Dilution (1Y)

1.60%

Diluted EPS (TTM)

-1.49

Peers (Alternatives to BeiGene)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
298.0B
1.4B
-3.25% 8.54%
-148.7
210.43
20.37% -37.45%
279.9B
58.1B
4.88% 1.38%
23.64
4.82
3.30% 2.55%
87.7B
12.2B
9.61% 20.63%
20.21
7.2
-24.26% -46.28%
80.8B
8.9B
6.80% 24.91%
24.32
9.05
17.91% 41.84%
23.5B
1.0B
-5.53% 16.05%
-20.81
22.69
22.88% -32.64%
11.5B
933.0M
2.93% 61.85%
-16.28
12.27
32.93% -67.99%
10.1B
1.9B
-9.77% 22.96%
13.92
5.23
14.88% 52.86%
MID-CAP
4.2B
504.0K
-19.59% 144.55%
-14.38
2.5K
-66.53% -22.12%
2.6B
363.3M
-18.37% -45.49%
-3.74
7.28
3.39% -55.81%
2.6B
204.0M
1.49% -34.21%
-4.68
12.78
13.30% 13.44%
2.3B
12.4M
-15.06% -52.42%
-3.05
181.9
- -27.34%
SMALL-CAP
1.7B
214.2M
4.81% 93.98%
20.42
7.92
52.10% 110.42%
412.2M
151.9M
1.98% -27.23%
-3.44
2.71
96.19% 40.75%
28.6M
-
145.52% 1270.00%
-0.67
19.11
-77.61% 7.22%
3.1M
94.6M
-20.08% -11.44%
-0.01
0.03
34.30% -80.65%

Financials for BeiGene

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue13.3%1,415,921,0001,249,805,0001,068,617,000877,037,0001,176,283,000
  S&GA Expenses1.8%1,277,852,0001,255,369,0001,201,704,0001,102,590,000990,123,000
  R&D Expenses1.0%1,640,508,0001,624,970,0001,550,544,0001,528,428,0001,459,239,000
EBITDA9.1%-1,842,279,000-2,025,714,000-1,926,567,000-1,870,492,000-
EBITDA Margin19.7%-1.30-1.62-1.80-2.13-
Earnings Before Taxes7.4%-1,961,037,000-2,116,876,000-1,998,716,000-1,921,702,000-1,438,588,000
EBT Margin18.2%-1.38-1.69-1.87-2.19-
Interest Expenses76.2%52,480,00029,779,00014,790,000-1,507,000-15,757,000
Net Income6.8%-2,003,815,000-2,149,158,000-2,029,716,000-1,948,594,000-1,457,816,000
Net Income Margin17.7%-1.42-1.72-1.86-2.18-
Free Cahsflow9.1%-1,822,053,000-2,005,322,000-1,897,517,000-1,926,065,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-5.2%6,3796,7267,3788,0218,536
  Current Assets-9.4%5,2075,7496,3466,9487,614
    Cash Equivalents-7.8%3,8704,1974,5314,3474,376
  Inventory-2.9%282291262246243
  Net PPE24.1%846682633625588
Liabilities-3.6%1,9962,0712,0762,1362,403
  Current Liabilities4.1%1,4691,4111,3981,3761,600
    LT Debt, Current-25.5%3294413814072,725
    LT Debt, Non Current593.3%1,4432081,2411,278202
Shareholder's Equity-5.8%4,3834,6555,1975,7746,133
  Retained Earnings-6.7%-7,080-6,635-5,971-5,400-5,076
  Additional Paid-In Capital0.8%11,54111,45211,35711,26811,191
Accumulated Depreciation5.0%150143138124-
Shares Outstanding0.5%1,3561,3501,3501,3351,335
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations11.2%-1,496-1,686-1,620-1,660-1,298
  Share Based Compensation5.2%303288277260241
Cashflow From Investing-6.1%1,0771,148966559641
Cashflow From Financing-100.5%-18.973,4763,4653,5183,637

Risks for BGNE

What is the probability of a big loss on BGNE?

100%


Probability that BeiGene stock will be more than 20% underwater in next one year

66.2%


Probability that BeiGene stock will be more than 30% underwater in next one year.

34.6%


Probability that BeiGene stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BGNE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if BeiGene was unfortunately bought at previous high price.

Drawdowns

Returns for BGNE

Cumulative Returns on BGNE

34.2%


7-Year Cumulative Returns

6.8%


5-Year Cumulative Returns

19.3%


3-Year Cumulative Returns

What are the long-term rolling returns for BGNE?

FIve years rolling returns for BeiGene.

Annualized Returns

Which funds bought or sold BGNE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
BAILLIE GIFFORD & CO
added
6.19
316,951,000
749,714,000
0.78%
2023-03-06
OLD MISSION CAPITAL LLC
new
-
5,767,270
5,767,270
0.16%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-0.45
74,000
193,000
-%
2023-02-28
Voya Investment Management LLC
sold off
-100
-631,000
-
-%
2023-02-24
National Pension Service
sold off
-100
-1,288,660
-
-%
2023-02-24
SRS Capital Advisors, Inc.
unchanged
-
100
1,100
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
new
-
1,980
1,980
-%
2023-02-21
MACQUARIE GROUP LTD
added
2.31
2,119,060
5,284,060
0.01%
2023-02-17
TRUIST FINANCIAL CORP
new
-
249,852
249,852
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
added
10.34
2,038
7,038
-%

1–10 of 42

Latest Funds Activity

Are funds buying BGNE calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BGNE
No. of Funds

BeiGene News

Nasdaq

J.P. Morgan Analysts Say These 2 Stocks Are Their Top Picks for 2023.

Nasdaq,
26 hours ago

The Pharma Letter

Nasdaq

Yahoo Finance

Schedule 13G FIlings of BeiGene

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
hhlr advisors, ltd.
10.9%
147,043,058
SC 13D/A
Feb 13, 2023
capital international investors
8.2%
110,215,170
SC 13G/A
Feb 10, 2023
oyler john
5.1%
70,026,397
SC 13G/A
Aug 16, 2022
hhlr advisors, ltd.
10.9%
147,035,258
SC 13D/A
Feb 14, 2022
oyler john
5.1%
69,558,605
SC 13G/A
Feb 11, 2022
capital international investors
7.8%
104,036,177
SC 13G/A
Feb 11, 2022
beigene, ltd.
5.1%
69,558,605
SC 13G/A
Feb 11, 2022
invesco ltd.
5.6%
39,028,821
SC 13G
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 16, 2021
capital international investors
7.6%
89,894,623
SC 13G/A

BGNE Fair Value

BeiGene fair value in different scenarios

The table shows the Fair Value estimates for BeiGene for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

0.97

-99.56%

1.20

-99.45%

1.95

-99.11%

3.33

-98.48%

6.11

-97.22%
Current Inflation

0.95

-99.57%

1.15

-99.48%

1.81

-99.18%

2.99

-98.64%

5.35

-97.56%
Very High Inflation

0.93

-99.58%

1.10

-99.50%

1.64

-99.25%

2.59

-98.82%

4.48

-97.96%

Historical BeiGene Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of BeiGene

View All Filings
Date Filed Form Type Document
Mar 20, 2023
4
Insider Trading
Mar 10, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Feb 27, 2023
10-K
Annual Report
Feb 27, 2023
8-K
Current Report
Feb 14, 2023
SC 13D/A
13D - Major Acquisition
Feb 13, 2023
SC 13G/A
Major Ownership Report
Feb 10, 2023
SC 13G/A
Major Ownership Report
Feb 10, 2023
SC 13G/A
Major Ownership Report
Jan 31, 2023
8-K
Current Report

Latest Insider Trading transactions for BGNE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-16
Wang Xiaodong
gifted
-
-
-67,444
-
2023-03-08
Wang Xiaodong
acquired
8,792
0.13
67,635
-
2023-03-08
Wang Xiaodong
sold
-15,287,300
226
-67,635
-
2023-03-01
Wang Julia Aijun
sold
-82,391
240
-343
chief financial officer
2023-01-12
Wang Xiaodong
sold
-1,302,580
260
-5,000
-
2023-01-11
Wang Xiaodong
sold
-631,647
252
-2,500
-
2023-01-10
Wang Xiaodong
sold
-400,152
250
-1,600
-
2023-01-10
OYLER JOHN
sold
-1,689,160
248
-6,797
chief executive officer
2023-01-10
OYLER JOHN
sold
-3,378,290
248
-13,594
chief executive officer
2023-01-09
Wang Xiaodong
sold
-225,000
250
-900
-

1–10 of 50

John V. Oyler
8200
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Beijing, China.

BGNE Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues   
Total revenues$ 1,415,921$ 1,176,283$ 308,874
Expenses   
Cost of sales - product286,475164,90670,657
Research and development1,640,5081,459,2391,294,877
Selling, general and administrative1,277,852990,123600,176
Amortization of intangible assets751750846
Total expenses3,205,5862,615,0181,966,556
Loss from operations(1,789,665)(1,438,735)(1,657,682)
Interest income (expense), net52,480(15,757)1,998
Other (expense) income, net(223,852)15,90437,490
Loss before income taxes(1,961,037)(1,438,588)(1,618,194)
Income tax expense42,77819,22810,397
Net loss(2,003,815)(1,457,816)(1,628,591)
Less: net loss attributable to noncontrolling interests00(3,617)
Net loss attributable to BeiGene, Ltd.$ (2,003,815)$ (1,457,816)$ (1,624,974)
Net loss per share attributable to BeiGene, Ltd., basic (in dollars per share)$ (1.49)$ (1.21)$ (1.50)
Net loss per share attributable to BeiGene, Ltd., diluted (in dollars per share)$ (1.49)$ (1.21)$ (1.50)
Weighted-average shares outstanding, basic (in shares)1,340,729,5721,206,210,0491,085,131,783
Weighted-average shares outstanding, diluted (in shares)1,340,729,5721,206,210,0491,085,131,783
Net loss per American Depositary Share (ADS), basic (in dollars per share)$ (19.43)$ (15.71)$ (19.47)
Net loss per American Depositary Share (ADS), diluted (in dollars per share)$ (19.43)$ (15.71)$ (19.47)
Weighted-average ADSs outstanding, basic (in shares)103,133,04492,785,38883,471,676
Weighted-average ADSs outstanding, diluted (in shares)103,133,04492,785,38883,471,676
Product revenue, net   
Revenues   
Total revenues$ 1,254,612$ 633,987$ 308,874
Collaboration revenue   
Revenues   
Total revenues$ 161,309$ 542,296$ 0

BGNE Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS
¥ in Thousands, $ in Thousands
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Current assets:  
Cash and cash equivalents$ 3,869,564$ 4,375,678
Short-term restricted cash196328
Short-term investments665,2512,241,962
Accounts receivable, net173,168483,113
Inventories282,346242,626
Prepaid expenses and other current assets216,553270,173
Total current assets5,207,0787,613,880
Long-term restricted cash5,2776,881
Property, plant and equipment, net845,946587,605
Operating lease right-of-use assets109,960117,431
Intangible assets, net40,61646,679
Other non-current assets170,413163,049
Total non-current assets1,172,212921,645
Total assets6,379,2908,535,525
Current liabilities:  
Accounts payable294,781262,400
Accrued expenses and other payables467,352558,055
Deferred revenue, current portion213,861187,414
Tax payable25,18921,395
Operating lease liabilities, current portion24,04121,925
Research and development cost share liability, current portion114,335120,801
Short-term debt328,969427,565
Total current liabilities1,468,5281,599,555
Non-current liabilities:  
Long-term debt209,148202,113
Deferred revenue, non-current portion42,026220,289
Operating lease liabilities, non-current portion34,51743,041
Deferred tax liabilities15,99614,169
Research and development cost share liability, non-current portion179,625269,561
Other long-term liabilities46,09554,234
Total non-current liabilities527,407803,407
Total liabilities1,995,9352,402,962
Commitments and contingencies
Equity:  
Ordinary shares, 0.0001 par value per share; 9,500,000,000 shares authorized; 1,356,140,180 and 1,334,804,281 shares issued and outstanding as of December 31, 2022 and 2021, respectively135133
Additional paid-in capital11,540,97911,191,007
Accumulated other comprehensive (loss) income(77,417)17,950
Accumulated deficit(7,080,342)(5,076,527)
Total equity4,383,3556,132,563
Total liabilities and equity$ 6,379,290$ 8,535,525